Valneva SE (VALN) Gross Profit (2021 - 2026)
Valneva SE (VALN) posted Gross Profit of $5.5 million for Q1 2026, up 95.6% sequentially from $2.8 million in Q4 2025, and down 79.92% YoY from $27.5 million in Q1 2025.
Valneva SE (VALN) Gross Profit (2021 - 2026) Analysis & Trends
Valneva SE has reported Gross Profit for 6 years, with the latest figure at $5.5 million in Q1 2026.
- Quarterly Gross Profit fell 79.92% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.3 million (down 61.24% YoY) and the FY2025 annual result came in at $59.1 million, down 15.7% from the prior year.
- Gross Profit advanced to $5.5 million in Q1 2026 per VALN's latest filing, from $2.8 million in the prior quarter.
- Over five years, Gross Profit peaked at $126.5 million in Q3 2022 and troughed at -$92.0 million in Q2 2022.
- A 5-year average of $13.0 million and a median of $14.0 million in 2023 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2022 and 2023: Gross Profit plunged 1937.35% in 2022, then jumped 261.9% in 2023.
- Over 5 years, Gross Profit stood at -$10.5 million in 2022, then surged by 261.9% to $17.0 million in 2023, then jumped by 47.83% to $25.2 million in 2024, then tumbled by 88.77% to $2.8 million in 2025, then surged by 95.6% to $5.5 million in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $5.5 million, $2.8 million, and -$2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Mn |
| Jun 30, 2026 | 1.86 Mn |
| Mar 31, 2026 | 5.53 Mn |
| Mar 31, 2026 | 5.53 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Sep 30, 2025 | -2.42 Mn |
| Sep 30, 2025 | -2.42 Mn |
| Jun 30, 2025 | 27.41 Mn |
| Jun 30, 2025 | 27.41 Mn |
| Mar 31, 2025 | 27.55 Mn |
| Mar 31, 2025 | 27.55 Mn |
| Dec 31, 2024 | 25.18 Mn |
| Dec 31, 2024 | 25.18 Mn |
| Sep 30, 2024 | 17.58 Mn |
| Sep 30, 2024 | 17.58 Mn |
| Jun 30, 2024 | 15.71 Mn |
| Jun 30, 2024 | 15.71 Mn |
| Mar 31, 2024 | 11.51 Mn |
| Mar 31, 2024 | 11.51 Mn |